Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

A. Di Cataldo, A. Agodi, J. Balaguer, A. Garaventa, M. Barchitta, V. Segura, M. Bianchi, V. Castel, A. Castellano, S. Cesaro, J. M. Couselo, O. Cruz, P. D'Angelo, B. Bernardi, J. Donat, N. G. de Andoin, M. I. Hernandez, M. Spina, M. Lillo, R. Lopez-AlmarazR. Luksch, S. Mastrangelo, E. Mateos, J. Molina, Carla Moscheo, Rosamaria Mura, F. Porta, G. Russo, Annalisa Tondo, M. Torrent, Simona Vetrella, J. A. Villegas, E. Viscardi, G. A. Zanazzo, A. Canete

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: SIOPEN INES protocol yielded excellent 5-year survival rates for
Original languageUndefined/Unknown
Pages (from-to)76-83
Number of pages8
JournalClinical and Translational Oncology
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Keywords

  • *Clinical Trials as Topic, *Gene Amplification, Biomarkers, Tumor/*genetics, Child, Child, Preschool, Combined Modality Therapy, Eligibility, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Metastatic, Neoplasm Staging, Neuroblastoma, Neuroblastoma/genetics/*mortality/secondary/therapy, N-Myc Proto-Oncogene Protein/*genetics, Prognosis, Survival, Survival Rate

Cite this